QGEN - Multiplikator forward rega marang pendapatan Qiagen N.V.

QGEN (Qiagen) - tandha merek perusahaan

Qiagen N.V. dominates the DNA diagnostics segment due to its extensive installed base of equipment. The forward P/S ratio reflects the market valuation of these assets, where the value 3.40 describes the current level. Revenue is based on a "razor-and-blade" model through the sale of consumables, while production automation ensures stable operating leverage and predictable business growth.

QGEN qiagen.com: Prakiraan rega marang pendapatan ing interval 04.07.2022 - 16.11.2026

QGEN (qiagen.com): rincian analitis lan laporan miturut indikator

- rega saham lan target rega konsensus:
Pambiji fundamental perusahaan:Qiagen N.V. QGEN
Sampel barang Qiagen N.V.

The non-cyclical nature of Qiagen N.V. (QGEN) business in molecular diagnostics ensures a stable revenue stream, minimizing the impact of macroeconomic shocks. The forward P/S ratio compares market capitalization with projected sales volume, allowing for an assessment of the cost of each unit of future revenue. By analyzing the company's expected P/S chart, an investor determines the degree of overpayment for the asset, finding the equilibrium point between risk and growth potential.

Analisis pesaing Qiagen N.V.

Multiplikator Forward P/S TEM (Tempus Labs)|Rega forward marang dodolan IONS|RGEN - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake Avidity Biosciences RNA|CRSP: Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan WGS|RARE (Ultragenyx Pharma) - Multiplikator Forward P/S|Multiplikator Forward P/S Beam Therapeutics Inc.|Rasio rega marang prakiraan pendapatan Sarepta Therapeutics Inc (SRPT)|Twist Bioscience - Kapitalisasi marang prakiraan pendapatan|10x Genomics Inc - Multiplikator forward rega marang pendapatan|NTLA (Intellia Therapeutics, Inc.) - Rega mangsa ngarep marang pendapatan|Stoke Corp - Multiplikator Forward P/S|BLFS (BioLife) - Kapitalisasi marang prakiraan pendapatan|wavelifesciences.com (WVE) - Rasio rega marang prakiraan pendapatan|MAZE - Rasio kapitalisasi marang dodolan sing dikarepake|SION (Sionna Therapeutics, Inc.) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Prime Medicine Corp (PRME)|Multiplikator Forward P/S TSHA|Multiplikator Forward P/S uniQure N.V. (QURE)|Rasio rega marang prakiraan pendapatan MeiraGTx Holdings plc MGTX|RGNX: Kapitalisasi marang prakiraan pendapatan|Solid Biosciences Inc - Multiplikator Forward P/S|OCGN - Multiplikator Forward P/S|PACB: Multiplikator Forward P/S|BNTC - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Design Therapeutics, Inc.|RCKT: Rega forward marang dodolan|Multiplikator forward rega marang pendapatan FDMT (4D Molecular Therapeutics, Inc.)|Lexeo Therapeutics, Inc. - Kapitalisasi marang prakiraan pendapatan|Rasio rega marang prakiraan pendapatan Korro Bio, Inc. KRRO|EDIT: Kapitalisasi marang prakiraan pendapatan|SLN - Rasio rega marang prakiraan pendapatan|Prakiraan rega marang pendapatan ProQR Therapeutics (PRQR)|CDXS (Codexis Bio) - Multiplikator forward rega marang pendapatan|Sangamo Therapeutics Inc. (SGMO) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan Nautilus Bio|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Metagenomi Therapeutics MGX|Rasio rega marang prakiraan pendapatan Precision BioSciences (DTIL)|GBIO - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Multiplikator Forward P/S BOLD (Boundless Bio, Inc)|XCUR - Multiplikator forward rega marang pendapatan|IMNN - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Phio Pharmaceuticals Corp|MBIO: Multiplikator Forward P/S|TransCode (RNAZ) - Multiplikator Forward P/S|BNGO (Bionano) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Applied DNA Sciences, Inc. APDN|Multiplikator Forward P/S BLUE|ImmunoPrecise Antibodies Ltd - Kapitalisasi marang prakiraan pendapatan|Rasio rega marang prakiraan pendapatan Omega Therapeutics OMGA|OMIC: Kapitalisasi marang prakiraan pendapatan|RGLS: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan SYRS (Syros Pharmaceuticals, Inc.)|Telesis Bio, Inc. (TBIO) - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan TCON (TRACON)|Rasio rega marang prakiraan pendapatan Unity Biotechnology, Inc.